2. Search Result
Search Result
Results for "

inward

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

6

Peptides

6

Natural
Products

4

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108608
    o-3M3FBS

    		Calcium Channel Others
    o-3M3FBS is the negative control of m-3M3FBS. o-3M3FBS inhibits inward and outward currents via mechanisms independent of PLC acting in an antagonistic manner. In contrast, o-3M3FBS also causes an increase in [Ca 2+]i in an agonistic manner .
    o-3M3FBS
  • HY-19434
    trans-ACPD

    Trans-(±)-ACP

    		 mGluR Metabolic Disease
    trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward current in cultured cerebellar Purkinje neurons.
    trans-ACPD
  • HY-N2338
    Cholesterol myristate

    Cholesteryl myristate; Cholesteryl tetradecanoate

    		 nAChR GABA Receptor Potassium Channel Endogenous Metabolite Cancer
    Cholesterol myristate is a natural steroid present in traditional Chinese medicine. Cholesterol myristate binds to several ion channels such as the nicotinic acetylcholine receptor, GABAA receptor, and the inward-rectifier potassium ion channel.
    Cholesterol myristate
  • HY-N4309A
    Lotusine hydroxide

    		Others Cardiovascular Disease
    Lotusine (hydroxide) is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine (hydroxide) shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .
    Lotusine hydroxide
  • HY-N6868
    Dimethyl lithospermate B

    dmLSB

    		 Sodium Channel Cardiovascular Disease
    Dimethyl lithospermate B (dmLSB) is a selective Na + channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .
    Dimethyl lithospermate B
  • HY-P5887
    Tertiapin-RQ

    		Potassium Channel Neurological Disease
    Tertiapin-RQ is an inward rectifier K + channel blocker peptide with antidepressive effect .
    Tertiapin-RQ
  • HY-N4309
    Lotusine

    		Others Cardiovascular Disease
    Lotusine is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .
    Lotusine
  • HY-12520B
    (R)-SKF 38393 hydrochloride

    (±)-SKF-38393 hydrochloride; SKF-38393A hydrochloride

    		 Dopamine Receptor Potassium Channel Neurological Disease
    (R)-SKF 38393 ((±)-SKF-38393) hydrochloride is a potent and selective D1 dopamine receptor antagonist. (R)-SKF 38393 hydrochloride inhibits G protein-coupled inwardly rectifying potassium (GIRK) channel .
    (R)-SKF 38393 hydrochloride
  • HY-103298
    MNI-caged kainate

    		Endogenous Metabolite Neurological Disease
    MNI-caged kainate is a photoprotected neuroactive amino acid with the activity to generate large inward currents. MNI-caged kainate can be released at the resting membrane potential of Purkinje cells and generate significant inward currents. The release of MNI-caged kainate results in approximately 40% of the current being generated through AMPA receptor activation. MNI-caged kainate is used to study fast synaptic receptor mechanisms. The photorelease time of MNI-caged kainate is in the sub-microsecond range, making it suitable for investigating the mechanisms of fast synaptic transmission .
    MNI-caged kainate
  • HY-116072
    Antiarrhythmic agent-2

    		Calcium Channel Cardiovascular Disease
    Antiarrhythmic agent-2 is a nonspecific Ca 2+ inward current blocker that inhibits ionic currents in sensory neuron membranes. Antiarrhythmic agent-2 can be used in the study of cardiovascular diseases, such as arrhythmias .
    Antiarrhythmic agent-2
  • HY-114633
    VU625

    		Potassium Channel Others
    VU625 is an inhibitor for potassium channel, that selectively inhibits mosquito Aedes aegypti inward rectifier potassium channel 1 (AeKir), with IC50 of 96.8 nM in HEK293 cell. VU625 can be used in development of insecticide .
    VU625
  • HY-107757
    GMQ

    		Sodium Channel Neurological Disease
    GMQ is a ASIC (acid-sensing ion) channel activator with an EC50 value of 1.83 mM for ASIC3 at pH 7.4. GMQ opens only ASIC3 but no other ASICs at pH 7.4. GMQ can be used for neurological disease research .
    GMQ
  • HY-129496
    NP-313

    		Thrombin Cardiovascular Disease
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
    NP-313
  • HY-139064
    NPBA

    		Potassium Channel Neurological Disease Inflammation/Immunology
    NPBA, a potassium K2P channel TASK-3 (KCNK9) agonist, is a tandem pore domain weak inward rectifying K + channel (TWIK2) channel blocker. NPBA suppresses NLRP3 inflammasome activation in macrophages .
    NPBA
  • HY-142050
    (R)-IDHP

    		Calcium Channel Cardiovascular Disease
    (R)-IDHP is an isomer of IDHP, a salvia metabolite that exerts vasorelaxant effects by inhibiting Ca 2+ release and Ca 2+ inward flow in voltage-dependent and receptor-operated calcium channels in vascular smooth muscle cells. IDHP is used in studies of cardiovascular disease .
    (R)-IDHP
  • HY-125176
    G907
    1 Publications Verification

    		 Bacterial Infection
    G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC50 value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket .
    G907
  • HY-17401
    Ranolazine dihydrochloride
    4 Publications Verification

    CVT 303 dihydrochloride; RS 43285

    		 Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine dihydrochloride
  • HY-127106
    VU0810464
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    VU0810464 is a potent and selective non-ureaG protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) activator. VU0810464 displays nanomolar potency for neuronal (EC50=165 nM) and GIRK1/4 (EC50=720 nM) channels with improved brain penetration .
    VU0810464
  • HY-W010950
    Flecainide
    2 Publications Verification

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .
    Flecainide
  • HY-W010950A
    Flecainide hydrochloride
    2 Publications Verification

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias .
    Flecainide hydrochloride
  • HY-12533
    Disopyramide
    1 Publications Verification

    Dicorantil; SC-7031

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide
  • HY-12533B
    Disopyramide hydrochloride

    Dicorantil hydrochloride; SC-7031 hydrochloride

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide hydrochloride is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide hydrochloride blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide hydrochloride inhibits HERG encoded potassium channels. Disopyramide hydrochloride also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide hydrochloride
  • HY-12533A
    Disopyramide phosphate
    1 Publications Verification

    Dicorantil phosphate; SC-7031 phosphate

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide phosphate
  • HY-B0280
    Ranolazine
    4 Publications Verification

    CVT 303; RS 43285-003

    		 Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine
  • HY-B0883
    Proflavine hemisulfate
    2 Publications Verification

    Proflavin hemisulfate; 3,6-Diaminoacridine hemisulfate

    		 Bacterial Potassium Channel Autophagy Infection Cancer
    Proflavine hemisulfate, an acridine dye, is a known DNA intercalating agent. Anti-microbial agent . Proflavine hemisulfate behaves as a pore blocker for Kir3.2. Proflavine hemisulfate is a potential lead compound for Kir3.2-associated neurological diseases .
    Proflavine hemisulfate
  • HY-B1741
    Proflavine
    2 Publications Verification

    3,6-Diaminoacridine

    		 Bacterial Fluorescent Dye Neurological Disease Cancer
    Proflavine, an acridine dye, is a known DNA intercalating agent. Anti-microbial agent . Proflavine behaves as a pore blocker for Kir3.2. Proflavine is a potential lead compound for Kir3.2-associated neurological diseases .
    Proflavine
  • HY-112705
    VU0529331

    		Potassium Channel Neurological Disease
    VU0529331 is a modestly selective non-GIRK1-containing G protein-gated, inwardly-rectifying, potassium channel (non-GIRK1/X) activator, with EC50s of 5.1 µM and 5.2 µM for GIRK2 and GIRK1/2 in HEK293 cells, respectively, also effective on GIRK4 homomeric channel .
    VU0529331
  • HY-W010950R
    Flecainide (Standard)

    		Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .
    Flecainide (Standard)
  • HY-17401S
    Ranolazine-d8 dihydrochloride

    CVT 303-dd8 dihydrochloride; RS 43285-d8

    		 Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine-d8 (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].
    Ranolazine-d8 dihydrochloride
  • HY-12533R
    Disopyramide (Standard)

    		Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Standard) is the analytical standard of Disopyramide. This product is intended for research and analytical applications. Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide (Standard)
  • HY-B0280S2
    Ranolazine-d3

    		Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
    Ranolazine-d3
  • HY-P2791
    Tertiapin (reduced)

    		Potassium Channel Neurological Disease Inflammation/Immunology
    Tertiapin (reduced) is a kind of synthesis of melittin, its Cys3-Cys14 and Cys5-Cys18 between containing a disulfide bond. Tertiapin (reduced) is a kind of inward rectifier potassium channels blockers, can block the activity of calcium activates large conductance potassium channels. Tertiapin (reduced) can be used for research in diseases such as rheumatoid arthritis and multiple sclerosis .
    Tertiapin (reduced)
  • HY-B0280S
    Ranolazine-d5

    CVT 303-d5; RS 43285-003-d5

    		 Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
    Ranolazine-d5
  • HY-B0280S1
    Ranolazine-d8

    		Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
    Ranolazine-d8
  • HY-B1741A
    Proflavine dihydrochloride

    3,6-Diaminoacridine dihydrochloride

    		 Bacterial Fluorescent Dye Infection
    Proflavine (3,6-Diaminoacridine) dihydrochloride, an acridine dye, is a DNA intercalating agent and Anti-microbial agent. Proflavine dihydrochloride behaves as a pore blocker for Kir3.2. Proflavine dihydrochloride is a potential lead compound for Kir3.2-associated neurological diseases .
    Proflavine dihydrochloride
  • HY-13422
    Zatebradine hydrochloride
    1 Publications Verification

    UL-FS-49; UL-FS-49CL

    		 HCN Channel Cardiovascular Disease
    Zatebradine (UL-FS-49 (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 values 1.96 μM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 μM, 2.21 μM, 1.90 μM and 1.88 μM, respectively .
    Zatebradine hydrochloride
  • HY-B0280R
    Ranolazine (Standard)

    		Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine (Standard)
  • HY-117403
    AB-FUBICA

    		Cannabinoid Receptor Potassium Channel
    AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC50 values of 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms .
    AB-FUBICA
  • HY-P1218
    Phrixotoxin 3

    		Sodium Channel Neurological Disease
    Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
    Phrixotoxin 3
  • HY-13422A
    Zatebradine
    1 Publications Verification

    UL-FS-49 free base; UL-FS-49CL free base

    		 HCN Channel Cardiovascular Disease
    Zatebradine (UL-FS-49 (free base); UL-FS-49CL (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 value of 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively .
    Zatebradine
  • HY-107717
    MNI-caged-NMDA

    		iGluR Neurological Disease
    MNI-caged-NMDA is a light-sensitive amino acid with rapid release properties suitable for use in the study of fast synaptic receptor mechanisms. MNI-caged-NMDA shows metered release of NMDA receptors, inducing rapid and sustained receptor activation in cerebellar interneurons. MNI-caged-NMDA is able to achieve rapid transient responses and generate large inward currents by local laser photolysis. The use of MNI-caged-NMDA can effectively study neurotransmitter signaling and its inhibitory effects on GABA-A receptors .
    MNI-caged-NMDA
  • HY-P1218A
    Phrixotoxin 3 TFA

    		Sodium Channel Neurological Disease
    Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
    Phrixotoxin 3 TFA
  • HY-172140
    Ebio3

    		Potassium Channel Neurological Disease
    Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC50 of 1.2 nM. Ebio3 binds to the KCNQ2 channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy .
    Ebio3
  • HY-A0170
    Trovafloxacin
    4 Publications Verification

    		 Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .
    Trovafloxacin
  • HY-103399
    Trovafloxacin mesylate
    4 Publications Verification

    		 Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .
    Trovafloxacin mesylate
  • HY-118814
    YM928

    		iGluR Neurological Disease
    YM928 is an orally active and noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. YM928 inhibits AMPA receptor-mediated toxicity in primary rat hippocampal cultures with an IC50 value of 2 μM. YM928 blocks AMPA-induced intracellular calcium influx with an IC50 value of 3 μM and antagonizes AMPA-induced inward currents with an IC50 value of 1 μM. YM928 is promising for research of neurological disorders .
    YM928
  • HY-135783
    AT 1001
    1 Publications Verification

    		 nAChR Neurological Disease
    AT 1001 is a high-affinity and selective antagonist of the α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) (Ki=2.64 nM). AT 1001 reversibly blocks inward currents induced by Epibatidine (HY-101078) in HEK cells transfected with α3β4 nAChR. AT-1001 dose-dependently inhibits nicotine self-administration behavior in rats without affecting food-reinforced responding. AT 1001 can be utilized in the research of nicotine addiction and smoking cessation therapies .
    AT 1001
  • HY-A0170R
    Trovafloxacin (Standard)

    		Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin (Standard) is the analytical standard of Trovafloxacin. This product is intended for research and analytical applications. Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .
    Trovafloxacin (Standard)
  • HY-12882A
    Ifenprodil tartrate
    5+ Cited Publications

    		 iGluR Potassium Channel Neurological Disease
    Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator .
    Ifenprodil tartrate
  • HY-18940
    Cilobradine

    Cilo

    		 Endogenous Metabolite Cardiovascular Disease
    Cilobradine (Cilo) is a HCN channel blocker with heart rate reducing activity. Cilobradine blocks the slow inward current of human HCN1, HCN2, HCN3, and HCN4 channels. Cilobradine has a slightly higher efficiency in blocking endogenous If in mouse sinoatrial node cells (IC50 value is 0.62μM). Cilobradine can dose-dependently reduce the heart rate from 600 to 200 bpm with an ED50 value of 1.2 mg/kg. Cilobradine induces arrhythmias at doses greater than 5 mg/kg, which are characterized by periodic fluctuations between T waves and P waves .
    Cilobradine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: